scholarly journals Potential Application of Probiotics in the Prevention and Treatment of Inflammatory Bowel Diseases

Ulcers ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-13 ◽  
Author(s):  
Silvina del Carmen ◽  
Alejandra de Moreno de LeBlanc ◽  
Anderson Miyoshi ◽  
Clarissa Santos Rocha ◽  
Vasco Azevedo ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Antioxidant Properties ◽  
Genetically Engineered ◽  
Treatment Protocols ◽  
Host Immune Responses ◽  
Beneficial Effects ◽  
Wide Range ◽  
Prevention And Treatment ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Lactic acid bacteria (LAB) represent a heterogeneous group of microorganisms that are naturally present in many foods and possess a wide range of therapeutic properties. The aim of this paper is to present an overview of the current expanding knowledge of the mechanisms by which LAB and other probiotic microorganisms participate in the prevention and treatment of inflammatory bowel diseases. These include changes in the gut microbiota, stimulation of the host immune responses, and reduction of the oxidative stress due to their antioxidant properties. A brief overview of the uses of genetically engineered LAB that produce either antioxidant enzymes (such as catalase and superoxide dismutase) or anti-inflammatory cytokines (such as IL-10) will also be discussed. This paper will show that probiotics should be considered in treatment protocols of IBD since they provide many beneficial effects and can enhance the effectiveness of traditional used medicines.

scholarly journals Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse

2020 ◽  
Vol 21 (8) ◽  
pp. 2940
Author(s):  
Antonelly Cassio Alves de Carvalho ◽  
Gabriela Achete de Souza ◽  
Samylla Vaz de Marqui ◽  
Élen Landgraf Guiguer ◽  
Adriano Cressoni Araújo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Diseases ◽  
Literature Search ◽  
Cannabis Sativa ◽  
Antioxidant Properties ◽  
Number Of Patients ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Inflammatory bowel diseases (IBD) are characterized by a chronic and recurrent gastrointestinal condition, including mainly ulcerative colitis (UC) and Crohn’s disease (CD). Cannabis sativa (CS) is widely used for medicinal, recreational, and religious purposes. The most studied compound of CS is tetrahydrocannabinol (THC) and cannabidiol (CBD). Besides many relevant therapeutic roles such as anti-inflammatory and antioxidant properties, there is still much controversy about the consumption of this plant since the misuse can lead to serious health problems. Because of these reasons, the aim of this review is to investigate the effects of CS on the treatment of UC and CD. The literature search was performed in PubMed/Medline, PMC, EMBASE, and Cochrane databases. The use of CS leads to the improvement of UC and CD scores and quality of life. The medical use of CS is on the rise. Although the literature shows relevant antioxidant and anti-inflammatory effects that could improve UC and CD scores, it is still not possible to establish a treatment criterion since the studies have no standardization regarding the variety and part of the plant that is used, route of administration and doses. Therefore, we suggest caution in the use of CS in the therapeutic approach of IBD until clinical trials with standardization and a relevant number of patients are performed.

scholarly journals Probiotics, prebiotics, synbiotics in prevention and treatment of inflammatory bowel diseases

2014 ◽  
Vol 60 (02) ◽  
pp. 3-19 ◽  
Author(s):  
Tanja Petreska Ivanovska ◽  
Maja Jurhar Pavlova ◽  
Kristina Mladenovska ◽  
Lidija Petrushevska-Tozi
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Functional Foods ◽  
Health Benefit ◽  
Positive Effects ◽  
Prevention And Treatment ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Highly Correlated ◽  
Functional Components ◽  
Care Costs

Probiotics, prebiotics, and synbiotics are functional components able to exert positive effects on human health. Numerous medical conditions lack effective and safe approaches for prevention or treatment, thus usage of probiotics, prebiotics, and synbiotics is an alternative. Further, the benefit related to the consumption of these compounds is associated with lower morbidity of chronic diseases and reduced health-care costs. Various types of mediums to deliver probiotics/synbiotics to the human GIT are used. Although capsules and tablets are frequently applied as delivery systems for probiotics, the major challenge of the commercial sector is to market new functional foods containing probiotics and/or prebiotics. Discovering of new probiotic/synbiotic functional foods is connected to the interest of the food industry to revitalize continuously through introduction of products with improved nutritional value and pleasant taste, but also with health benefit for the consumers. The review provides insights and new perspectives in respect to usage of functional components and foods in prevention and treatment of inflammatory bowel diseases (IBD) that are highly correlated with the modern lifestyle. The therapeutic and safety properties of probiotics and prebiotics, their role in pathogenesis of IBD, potential to prevent and treat these diseases as well as postulated mechanisms of action will be discussed, highlighting the main areas in which further research is an emergence.

scholarly journals Omega Fatty Acids and Inflammatory Bowel Diseases: An Overview

2019 ◽  
Vol 20 (19) ◽  
pp. 4851 ◽  
Author(s):  
Ledyane Taynara Marton ◽  
Ricardo de Alvares Goulart ◽  
Antonelly Cassio Alves de Carvalho ◽  
Sandra Maria Barbalho
Keyword(s):  
Fatty Acids ◽  
Inflammatory Bowel Diseases ◽  
Intestinal Inflammation ◽  
Omega 3 ◽  
Beneficial Effects ◽  
Ω3 Fatty Acids ◽  
Number Of Patients ◽  
Bowel Diseases ◽  
Inflammatory Processes ◽  
Inflammatory Bowel

Inflammatory bowel diseases (IBD) are chronic, inflammatory processes that affect the gastrointestinal tract and are mainly represented by ulcerative colitis (UC) and Crohn’s disease (CD). Omega 3 (ω3) fatty acids (eicosapentanoic acid and docosahexaenoic acid) show an indispensable role in the inflammatory processes and, for these reasons, we aimed to review the effects of these acids on UC and CD. Databases such as PUMED and EMBASE were searched, and the final selection included fifteen studies that fulfilled the inclusion criteria. The results showed that ω3 fatty acids reduce intestinal inflammation, induce and maintain clinical remission in UC patients, and are related with the reduction of proinflammatory cytokines, decrease disease activity and increase the quality of life of CD patients. Furthermore, the consumption of these fatty acids may be related to a reduced risk of developing IBD. Many studies have shown the beneficial effects of ω3 as adjunctive in the treatment or prevention of UC or CD. Nevertheless, most were performed with a small number of patients and there are many variations in the mode of consumption, the type of food or the type of formulation used. All these factors substantially interfere with the results and do not allow reliable comparisons.

Anti-inflammatory effects of purple sweet potato anthocyanin extract in DSS-induced colitis: modulation of commensal bacteria and attenuated bacterial intestinal infection

2021 ◽  
Author(s):  
jingjing Mu ◽  
jingwen xu ◽  
linlin wang ◽  
Caifa Chen ◽  
Ping Chen
Keyword(s):  
Gut Microbiota ◽  
Sweet Potato ◽  
Inflammatory Bowel Diseases ◽  
Commensal Bacteria ◽  
Intestinal Infection ◽  
Beneficial Effects ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Anti Inflammatory ◽  
Purple Sweet Potato

The purple sweet potato anthocyanin has been acknowledged for its beneficial effects on human inflammatory bowel diseases (IBD). Although the ability of anthocyanin in modulating gut microbiota has been reported,...

GLUT5 is a determinant of dietary fructose-mediated exacerbation of experimental colitis

2021 ◽  
Author(s):  
Srijani Basu ◽  
Catherine Liu ◽  
Xi Kathy Zhou ◽  
Ryohei Nishiguchi ◽  
Taehoon Ha ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Experimental Colitis ◽  
Fecal Microbiota ◽  
Genetically Engineered ◽  
Western Diet ◽  
High Fructose ◽  
Genetically Engineered Mice ◽  
Dietary Fructose ◽  
Bowel Diseases ◽  
Inflammatory Bowel

The western diet has been suggested to contribute to the rising incidence of Inflammatory Bowel Diseases. This has led to the hypothesis that fructose, a component of the western diet, could play a role in the pathogenesis of Inflammatory Bowel Diseases. A high fructose diet is known to exacerbate experimental colitis. This study tested whether the expression of GLUT5, the fructose transporter, is a determinant of the severity of experimental colitis during elevated fructose consumption and whether ileal inflammation is associated with altered GLUT5 expression in Crohn's Disease. Studies in genetically engineered mice showed that in comparison to Glut5+/+ mice, feeding a 15 kcal% fructose diet to Glut5-/- mice led to worse dextran sodium sulfate (DSS)-induced colitis. This effect was associated with elevated levels of colonic fructose and a shift in the fecal microbiota in Glut5-/- mice. Importantly, treatment with broad-spectrum antibiotics protected against the worsening of colitis mediated by dietary fructose in Glut5-/- mice. Gene expression analysis revealed that GLUT5 levels are reduced in patients with Crohn's ileitis. Moreover, levels of GLUT5 negatively correlated with levels of pro-inflammatory mediators. Collectively, these results demonstrate that dietary constituent (fructose)-host gene (GLUT5) interactions can shape the colonic microbiota thereby impacting the severity of colitis.

scholarly journals Improving the Efficacy of Mesenchymal/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases

Biomedicines ◽  
2021 ◽  
Vol 9 (11) ◽  
pp. 1507
Author(s):  
Mercedes Lopez-Santalla ◽  
Marina Inmaculada Garin
Keyword(s):  
Clinical Trials ◽  
Immune Responses ◽  
Inflammatory Bowel Diseases ◽  
Intestinal Inflammation ◽  
The Novel ◽  
Beneficial Effects ◽  
Commensal Microbiota ◽  
Bowel Diseases ◽  
Inflammatory Processes ◽  
Inflammatory Bowel

Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients treated with biologicals experienced drawbacks including loss of response, while others can develop severe side effects. Hence, novel effective treatments are highly needed. Mesenchymal stem/stromal cell (MSCs) therapy is an innovative therapeutic alternative currently under investigation for IBD. MSCs have the inherent capacity of modulating inflammatory immune responses as well as regenerating damaged tissues and are therefore a prime candidate to use as cell therapy in patients with IBD. At present, MSC-based therapy has been shown preclinically to modulate intestinal inflammation, whilst the safety of MSC-based therapy has been demonstrated in clinical trials. However, the successful results in preclinical studies have not been replicated in clinical trials. In this review, we will summarize the protocols used in preclinical and clinical trials and the novel approaches currently under investigation which aim to increase the beneficial effects of MSC-based therapy for IBD.

scholarly journals Precision medicine and inflammatory bowel diseases: concept, strategies, future

2021 ◽  
Vol 1 (6) ◽  
pp. 121-129
Author(s):  
G. R. Bikbavova ◽  
M. A. Livzan ◽  
D. G. Novikov ◽  
E. A. Bambulskaya
Keyword(s):  
Precision Medicine ◽  
Inflammatory Bowel Diseases ◽  
Scientific Information ◽  
Treatment Strategies ◽  
Wide Range ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
New Treatment ◽  
Personalized Approach ◽  
The Right

With the advent of modern cellular and genomic technologies, we have become participants in the integration of such areas as personalized, predictive, preventive, and precision medicine (referred to as 4P-medicine), into practical healthcare. In replace of the classic methods of diagnosis and treatment of diseases comes medicine, which makes it possible to predict (anticipate) the disease, and a personalized approach to each patient, taking into account their genetic, biochemical and physiological uniqueness. Precision medicine aims to improve the quality of medical care by opening up an individual approach to the patient and covers a wide range of areas, including drug therapy, genetics, and cause-and-effect relationships in order to make the right decisions based on evidence. 4P-medicine combines knowledge in the field of proteomics, metabolomics, genomics, bioinformatics with classical approaches of anatomy, therapy, laboratory and instrumental diagnostics as well as public health. The purpose of this review is to analyze and summarize the information available to date and to present examples of the application of modern approaches of medicine into clinical practice by diving into the example of inflammatory bowel diseases (IBD). The search for literature containing scientific information about relevant studies was conducted in the PubMed and Google Scholar systems with the use of the following keywords: precision medicine, 4P medicine, inflammatory bowel diseases. Despite significant progress in medicine in general, there is still a long way to go before implementing the principles of precision medicine in the field of IBD, since many clinicians continue to treat patients with IBD symptomatically. However, the use of specific biomarkers and new treatment strategies as described in the review, can significantly accelerate this path and contribute to the improvement of diagnostic and therapeutic approaches.

scholarly journals Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021)

2021 ◽  
Vol 49 ◽  
Author(s):  
E. A. Belousova ◽  
I. G. Kozlov ◽  
D. I. Abdulganieva ◽  
O. P. Alexeeva ◽  
I. V. Gubonina ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Clinical Guidelines ◽  
Biological Treatment ◽  
Genetically Engineered ◽  
Treatment Sequence ◽  
Patient Profile ◽  
Depth Analysis ◽  
Bowel Diseases ◽  
Inflammatory Bowel

On May 22, 2021, the Expert Board met in St. Petersburg to discuss their position on immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases (IBD). The Expert Board aimed at discussion of current strategies, development of a consensus on determination of an adequate biological treatment sequence for IBD. The main topics of the agenda were the contribution of immune system to the pathophysiology of Crohn's disease, ulcerative colitis and their complications, efficacy of genetically engineered biological agents (GEBA) at various stages of IBD management. Participation of the leading Russian experts in IBD, as well as involvement of other specialties, made it possible to consider the topic by a multidisciplinary team, with an in-depth analysis of IBD pathophysiology, to better understand the course of the disease in some contradictory situation, for instance, when clinical remission is not associated with an endoscopically confirmed remission. One of the expected effects of this Expert Board meeting would be an improvement of GEBA administration in clinical practice, mostly due to the modification of clinical guidelines. This would ascertain and confirm the algorithms for GEBA administration for IBD, including the optimal treatment sequence depending on an agent’s mechanism of action and the patient profile. The clarification of the optimal GEBA sequence in the clinical guidelines could lead to more frequent GEBA administration in local medical clinics and institutions in the regions, where GEBA are used insufficiently due to little experience and absence of their precise positioning in the clinical guidelines.

Sign in / Sign up

Export Citation Format

Share Document